AURK inhibitors thus hold considerable promise for prolonging the efficacy of third generation EGFR TKIs via their ability to target both Rb1-deficient clones that are prone to SCLC transformation and bulk Rb1-proficient cells that upregulate AURKA during EGFR TKI treatment. This evidence concerns the gene AURKA and small cell lung carcinoma.